Ewing´s sarcoma metastatic

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
2 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 2
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Kinase inhibitor 1 substance
RAF/BRAF inhibitor 1 substance
Phase II/III: 1 Phase II: 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II/III

1 trial
  • The University Of Birmingham Academic
    LENVATINIB
    2024-516078-31-00 10 countries 2015 n=436
    Recruiting

Phase II

2 trials
  • Instytut Matki I Dziecka Academic
    IMP not specified
    2024-514720-17-00 1 country 2022 n=30
    Ended
  • Unicancer Academic
    REGORAFENIB
    2024-513455-33-00 1 country 2014 n=159
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
The University Of Birmingham Academic 1 Phase II/III 1
Instytut Matki I Dziecka Academic 1 Phase II 0
Unicancer Academic 1 Phase II 0
New trials by year
2022
1
← All indication landscapes